Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

5601 - mRNA capture sequencing enabled liquid biopsy screening

Date

11 Sep 2017

Session

Poster display session

Presenters

Jo Vandesompele

Citation

Annals of Oncology (2017) 28 (suppl_5): v449-v452. 10.1093/annonc/mdx378

Authors

J. Vandesompele

Author affiliations

  • Research And Development, Biogazelle, 9052 - Zwijnaarde/BE
More

Resources

Abstract 5601

Background

In contrast to general belief, a substantial part of the human protein coding transcriptome is abundantly present in the blood as extracellular mRNA, ready to exploited. It is well known that cancer cells actively and passively release RNA cargo into circulation and their detection may inform on the patient disease status.

Methods

We developed and applied a probe based RNA capture sequencing method as a sensitive RNA sequencing workflow to study thousands of transcripts in cell-free RNA from cancer patients’ plasma. The method is based on exome-style enrichment of a randomly primed cDNA library with preservation of strandedness information. More than one million capture probes target 21,000 human messenger RNA and 60,000 human long non-coding RNA genes. Apart from RNA abundance profiling, this type of data can also be used to detect structural RNA variants, such as somatic mutations, fusion genes, and RNA editing events, all known to play an important role in cancer.

Results

On average, between 6000-10,000 RNA genes are reproducibly detected in 0.2 ml of plasma. Detection and coverage sensitivity is greatly increased by using larger plasma volume and improved adaptor ligation strategies. We also observed a positive correlation between number of platelets in plasma and detected genes and variants, in line with their tumor-educated nature. Our benchmarked RNA variant pipeline identifies thousands of germline and somatic variants in circulating mRNA. A dedicated titration experiment in which plasma from cancer and healthy individuals were mixed in known ratios demonstrates excellent quantitative performance. Pronounced RNA abundance differences and enriched pathways are observed between cancer types and during treatment. The RNA capture sequencing also works on other body fluids, such as urine and serum, and simultaneous targeting of mRNA and lncRNA provides substantial enrichment of otherwise low-abundant lncRNAs.

Conclusions

RNA capture sequencing of liquid biopsies is a promising new application to support precision oncology and is expected to enhance therapy stratification, treatment response monitoring and early detection of relapse.

Clinical trial identification

Legal entity responsible for the study

Biogazelle and Ghent University

Funding

Biogazelle, Illumina

Disclosure

J. Vandesompele: Apart from professorship at Ghent University, co-founder and part-time CSO at Biogazelle, a Ghent University spin-off company.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.